622-52-6

Basic information

• Product Name: 4-METHYLPHENYLTHIOUREA
• Synonyms: P-TOLYLTHIOUREA;N-(4-METHYLPHENYL)THIOUREA;1-(P-TOLYL)THIOUREA;2-THIO-1-P-TOLYLUREA;1-(4-METHYLPHENYL)-2-THIOUREA;4-METHYLPHENYLTHIOUREA;2-thio-1-p-tolyl-ure;n-p-tolylthiourea
• CAS NO: 622-52-6
• Molecular Formula: C₈H₁₀N₂S
• Molecular Weight: 166.24
• EINECS: 210-740-8
• Mol File: 622-52-6.mol
• Article Data: 72

Chemical Properties

• Melting Point: 186 °C
• Boiling Point: 282.5 °C at 760 mmHg
• Flash Point: 124.6 °C
• Appearance: /
• Density: 1.242 g/cm³
• Vapor Pressure: 0.00335mmHg at 25°C
• Refractive Index: 1.696
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: almost transparency in hot Methanol
• PKA: 13.39±0.70(Predicted)
• BRN: 2086619
• CAS DataBase Reference: 4-METHYLPHENYLTHIOUREA(CAS DataBase Reference)
• NIST Chemistry Reference: 4-METHYLPHENYLTHIOUREA(622-52-6)
• EPA Substance Registry System: 4-METHYLPHENYLTHIOUREA(622-52-6)

Safety Data

• Hazard Codes: Xi
• Statements: 25
• Safety Statements: 20-36-45-60
• RIDADR: 2811
• RTECS: YU3325000
• HazardClass: 6.1
• PackingGroup: III
• Hazardous Substances Data: 622-52-6(Hazardous Substances Data)

Usage

General Description

4-METHYLPHENYLTHIOUREA is a chemical compound with the molecular formula C8H10N2S. It is a member of the thiourea family and is commonly used as a reagent in organic synthesis, particularly in the production of heterocyclic compounds. 4-METHYLPHENYLTHIOUREA is a white crystalline solid that is soluble in organic solvents and has a wide range of applications, including as a catalyst in chemical reactions, a precursor to pharmaceuticals, and as an intermediate in the production of dyes and pigments. It is also used in the synthesis of rubber chemicals and as a component in the production of pesticides and herbicides. Additionally, it has been studied for its potential use in anti-cancer therapy and as an anti-diabetic agent.

InChI:InChI=1/C8H10N2S/c1-6-2-4-7(5-3-6)10-8(9)11/h2-5H,1H3,(H3,9,10,11)

Upstream product

• 13037-22-4 methyl (N-(4-methylphenyl))dithiocarbamate 
• 14185-56-9 1-acetyl-3-(4-methylphenyl)thiourea 
• 540-23-8 p-toluidine hydrochloride 
• 1147550-11-5 ammonium thiocyanate 
• 622-59-3 1-isothiocyanato-4-methylbenzene 
• 333-20-0 potassium thioacyanate 
• 106-49-0 p-toluidine 
• 17356-08-0 thiourea 
• 14327-06-1 1-tert-butyl-3-p-tolylthiourea 
• 14294-26-9 N-(p-Tolyl)-N'-(tert.-pentyl)-thioharnstoff 
• 6281-61-4 1-benzoyl-3-(4-methylphenyl)thiourea 
• 824-88-4 O-phenyl carbamothioate 
• 124-41-4 sodium methylate 
• 2941-78-8 2-Amino-5-methylbenzoic acid 

Downstream Products

• 99982-53-3 3-p-tolylcarbamimidoylmercapto-propane-1-sulfonic acid 
• 112584-15-3 N-(p-tolyl)thiazol-2-amine 
• 2536-91-6 6-methylbenzothiazol-2-ylamine 
• 39889-77-5 1-p-tolyl-1H-tetrazol-5-ylamine 
• 109497-76-9 N,N''-di-p-tolyl-μ-disulfido-dicarboxamidine; dihydrobromide 
• 622-59-3 1-isothiocyanato-4-methylbenzene 
• 10532-64-6 N-(4-methylphenyl)cyanamide 
• 17385-68-1 2-(4-tolylamino)thiazol-4-one 
• 100061-42-5 (4-methyl-thiazol-2-yl)-p-tolyl-amine 
• 73318-36-2 N-(4-methylphenyl)-S-methylisothiourea 
• 16240-04-3 3-(4-methylphenyl)thiazolidine-2,4-dione 
• 20765-47-3 (N-p-tolyl-carbamimidoylmercapto)-acetic acid 
• 16098-04-7 2-[N-(p-methylphenylamino)]-4-phenyl-thiazole 
• 92437-64-4 1-pTolyl-5-furfuryliden-thiohydantoin 

Relevant articles and documents

Design, synthesis, and antipoliferative activities of novel substituted imidazole-thione linked benzotriazole derivatives

A new series of benzotriazole moiety bearing substituted imidazol-2-thiones at N1 has been designed, synthesized and evaluated for in vitro anticancer activity against the different cancer cell lines MCF-7(breast cancer), HL-60 (Human promyelocytic leukemia), and HCT-116 (colon cancer). Most of the benzotriazole analogues exhibited promising antiproliferative activity against tested cancer cell lines. Among all the synthesized compounds, BI9 showed potent activity against the cancer cell lines such as MCF-7, HL-60 and HCT-116 with IC50 3.57, 0.40 and 2.63 μM, respectively. Compound BI9 was taken up for elaborate biological studies and the HL-60 cells in the cell cycle were arrested in G2/M phase. Compound BI9 showed remarkable inhibition of tubulin polymerization with the colchicine binding site of tubulin. In addition, compound BI9 promoted apoptosis by regulating the expression of pro-apoptotic protein BAX and anti-apoptotic proteins Bcl-2. These results provide guidance for further rational development of potent tubulin polymerization inhibitors for the treatment of cancer.

Green and efficient synthesis of thioureas, ureas, primary: O -thiocarbamates, and carbamates in deep eutectic solvent/catalyst systems using thiourea and urea

An efficient and general catalysis process was developed for the direct preparation of various primary O-thiocarbamates/carbamates as well as monosubstituted thioureas/ureas by using thiourea/urea as biocompatible thiocarbonyl (carbonyl) sources. This procedure used choline chloride/tin(ii) chloride [ChCl][SnCl2]2 with a dual role as a green catalyst and reaction medium to afford the desired products in moderate to excellent yields. Moreover, the DES can be easily recovered and reused for seven cycles with no significant loss in its activity. Besides, the method shows very good performance for synthesizing the desired products on a large scale.

Synthetic (E)-3-phenyl-5-(phenylamino)-2-styryl-1,3,4-thiadiazol-3-ium chloride derivatives as promising chemotherapy agents on cell lines infected with HTLV-1

Synthesis of four compounds belonging to mesoionic class, (E)-3-phenyl-5-(phenylamino)-2-styryl-1,3,4-thiadiazol-3-ium chloride derivatives (5a-d) and their biological evaluation against MT2 and C92 cell lines infected with human T-cell lymphotropic virus type-1 (HTLV-1), which causes adult T-cell leukemia/lymphoma (ATLL), and non-infected cell lines (Jurkat) are reported. The compounds were obtained by convergent synthesis under microwave irradiation and the cytotoxicity was evaluated using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays. Results showed IC50 values of all compounds in the range of 1.51-7.70 μM in HTLV-1-infected and non-infected cells. Furthermore, it was observed that 5b could induce necrosis after 24 h for Jurkat and MT2 cell lines. The experimental (fluorimetric method) and theoretical (molecular docking) results suggested that the mechanism of action for 5b could be related to its capacity to intercalate into DNA. Moreover, the preliminary pharmacokinetic profile of the studied compounds (5a-d) was obtained through human serum albumin (HSA) binding affinity using multiple spectroscopic techniques (circular dichroism, steady-state and time-resolved fluorescence), zeta potential and molecular docking calculations. The interaction HSA:5a-d is spontaneous and moderate (Ka ～ 104 M-1) via a ground-state association, without significantly perturbing both the secondary and surface structures of the albumin in the subdomain IIA (site I), indicating feasible biodistribution in the human bloodstream.